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Hudson, MD; Windsor Westbrook Sherrill, PhD, MBA, MHA; Lori Dickes, PhD, MAAE
Background: Few coordinated treatment programs address the needs of infants and families struggling with the effects
of substance use. In 2003 a large Southeastern regional hospital launched the Managing Abstinence in Newborns (MAiN)
program, providing multidisciplinary, coordinated, community-based care for neonatal abstinence syndrome (NAS). A hypothesis-
generating study was conducted to compare the outcomes of MAiN infants to comparable NAS infants receiving traditional
care from 2006 through 2014 in South Carolina.
Methods: De-identiﬁed sociodemographic and clinical data on MAiN infants, as well as NAS infants not treated with
MAiN, were obtained from South Carolina statewide databases. Study measures included medical and safety outcomes, health
services utilization, child protective services involvement, emergency services utilization, and inpatient readmissions.
Results: Some 110 infants were identiﬁed who received the MAiN intervention and 356 NAS infants, also in South Caro-
lina, who were potentially MAiN eligible. Overall, there were no signiﬁcant differences in the two groups regarding medical
or safety outcomes or child protective services involvement. Traditional care NAS infants were more likely to be treated in
a higher-level nursery (68.8% vs. 0%). MAiN infants had $8,204 less per birth in median charges (p < 0.001) than the tra-
ditional care NAS infants. MAiN infants also had a lower percentage of ED visits (p = 0.01) assessed as possibly or likely
NAS related compared to traditional care NAS infants.
Conclusion: This study demonstrates the potential value of implementing the MAiN model in eligible NAS infants. With
no difference in medical and safety outcomes and a signiﬁcant reduction in charges, the MAiN model can be considered
safe and cost-effective.
Prescription and nonprescription opioid use and depen-dence is increasing in women of childbearing age and
during pregnancy.1 The Centers for Disease Control and Pre-
vention reports that, from 2008 to 2012, more than one
quarter of privately insured and one third of Medicaid-
enrolled women of childbearing age ﬁlled an opioid
prescription written by a health care provider.2 For preg-
nant women with opioid use disorders, methadone or
buprenorphine maintenance therapy is considered stan-
dard of care.3 Although maintenance therapy improves an
opioid-dependent woman’s chances for a successful preg-
nancy, fetal opioid exposure can result in neonatal abstinence
syndrome (NAS), a condition that results when a depen-
dent newborn is no longer exposed to substances used by
the mother during pregnancy.4 According to the Tennessee
Department of Health’s 2015 NAS surveillance report, more
than two thirds of NAS cases statewide were attributable to
supervised opioid replacement or pain therapy.5 Earlier sources
have estimated that 48% to 94% of neonates exposed to
opioids prenatally develop NAS.6,7
In recent years, NAS rates have increased rapidly across
the United States, increasing from 1.2 per 1,000 hospital
births in 2000 to 5.8 per 1,000 hospital births in 2012.8,9
The NAS epidemic is alarming both because of the sever-
ity of the neonate’s medical withdrawal experience and because
the majority of NAS cases are covered by Medicaid, a pub-
licly provided state health insurance program. In 2012
Medicaid was the primary payer for 81% of NAS cases, with
mean hospital charges of $66,700 per infant and $93,400
per pharmacologically treated NAS infant.9 South Caro-
lina is in a region with one of the highest NAS rates in the
country.9,10
The majority of birthing centers are not skilled in de-
tecting or treating NAS; observation and treatment protocols
vary by institution, state, and country.11 The conventional
approach is to manage affected infants in level II–IV nurs-
eries while withholding pharmacologic treatment until clear
objective evidence of NAS is observable, typically two to ﬁve
days after birth. Full withdrawal usually results in vomit-
ing, diarrhea, skin abrasions, perianal maceration, disorganized
suck patterns, irritability and sleeplessness, elevated muscle
tone, and signiﬁcant weight loss.12 There are few coordi-
nated and collaborative programs to address the broad range
of needs for infants and their families struggling with the
effects of substance abuse issues during pregnancy,
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hospitalization, and postnatal periods. Medication used to
treat NAS varies by hospital. In a study conducted by Patrick
et al. of 1,424 NAS infants from 14 children’s hospitals, 6
of the hospitals used methadone and 6 used morphine to
treat NAS. When compared to NAS infants who had been
treated initially with morphine, infants treated with meth-
adone had a shorter length of treatment and shorter length
of stay (LOS).11
In 2003 a large Southeastern regional hospital launched
the Managing Abstinence in Newborns (MAiN) program,
which provides multidisciplinary, coordinated, community-
based care for infants at high risk for opioid withdrawal and
their families within a mother/baby unit. MAiN’s three es-
sential elements are early treatment (methadone administered
within 48 hours of birth), the option to room in with the
mother for the entire hospitalization, and a combined
inpatient/outpatient wean. The objective of the current study
was to compare MAiN infants to NAS infants who were po-
tentially eligible for MAiN but received traditional care in
other South Carolina hospitals between 2006 and 2014. This
study ﬁlls a gap in the literature by combining supportive
care environmental elements described in other studies12,13
with the concept of anticipatory weaning for managing pre-
sumed opioid dependence due to antenatal exposure.14
METHODS
MAiN Model for Early Treatment Description
In 2003 a multidisciplinary team developed the MAiNmodel,
an early treatment model for infants at high risk for opioid
withdrawal. MAiN is based on the theory that neonates who
are chronically exposed to long-acting opioids in late ges-
tation should be considered dependent, as research has
demonstrated signiﬁcant transfer of opioids across the
placenta.15 The team does not presume that all substance-
exposed newborns will require or beneﬁt from treatment;
only those with “presumed opioid dependence” at birth after
high levels of opioid exposure in late gestation. Early meth-
adone treatment (within 48 hours of birth) and subsequent
weaning may prevent severe opioid withdrawal and its
complications.16 The pharmacologic approach is similar to
the stabilization and weaning process used for neonates with
iatrogenic opioid dependence. We conclude that regardless
of the source (intravenous or placental transfer), a newborn
with chronic continuous opioid exposure may be pre-
sumed to be opioid dependent.
The MAiN care protocol is consistent with many ele-
ments cited in a Joint Commission Quick Safety advisory,
which recommends a multidisciplinary treatment ap-
proach combined with maternal participation, protocol-
based drug weaning, “rooming in” and maternal-dyad care,
standard treatment protocols, combined inpatient and out-
patient care, and education of staff speciﬁc to treatment
standards.17 All substance-exposed infants, including those
treated with the MAiN intervention, are cared for in a
supportive and low-stimulation environment, which in-
cludes rooming in with mother on a 24-hour basis until she
is discharged (and for the entire newborn stay when appro-
priate), low lighting and noise levels, frequent skin-to-skin
care and holding, swaddling, breastfeeding (if not contra-
indicated), paciﬁer use (if needed), and minimized sleep
interruptions (such as exams). All MAiN–treated new-
borns have continuous monitoring of heart rate and breathing
to alert staff to events potentially related to withdrawal, med-
ication side effects, or other safety events (such as maternal
overlay). The study hospital is Baby-Friendly designated18;
for example, mother and baby are together for 23–24 hours
per day, and parents are the primary caregivers as long as
they are rooming in with the baby.
MAiN eligibility criteria include that a neonate must be
at least 35 weeks completed gestation and have no other con-
ditions at birth that require intensive care. In addition, the
neonate should be considered high risk for opioid with-
drawal, which includes mothers taking at least 20 mg of
methadone per day or at least 9 mg of buprenorphine per
day for at least two weeks immediately prior to delivery. The
early treatment thresholds were established in 2004 and were
based on the experience and observations of local newborn
hospitalists and pediatric pharmacists, well before NAS was
a research focus. In 2012 the American Academy of Pedi-
atrics recommended that each unit establish a threshold for
treatment of NAS cases and made recommendations for man-
aging (with an oral wean) newborns with presumed opioid
dependence.14 The two weeks is a rough parallel to the stan-
dard that if an infant is exposed to IV fentanyl for nine days
or more, he or she is presumed to be dependent and needs
to be weaned.14 Approximately 25% of NAS–diagnosed
infants met the MAiN eligibility criteria during the study
period (2006–2014).
Neonates eligible for MAiN are admitted to the low-
acuity Mother/Baby Unit and are offered early methadone
treatment and extended maternal stay for the duration of
the birth hospitalization. All neonates receive low-stimulation
supportive care and are managed by a pediatrician. Within
6–48 hours of birth, infants exposed to maternal metha-
done doses of 60 mg or higher are initiated on 0.1 mg/kg/
dose every 6 hours; those exposed to buprenorphine or a lower
methadone dose receive 0.05 mg/kg/dose every 6 hours. Staff
routinely perform urine and meconium drug screening,
perform prescription monitoring database queries, and com-
plete a social work evaluation for all families. Continuous
apnea and bradycardia monitoring is provided in the moth-
er’s room, and modiﬁed Finnegan scoring is performed every
4 hours. The Finnegan score is a 31-item scale designed to
quantify the severity of NAS and to guide treatment.19
Breastfeeding is encouraged and supported.
Dosing adjustments are made for signs of poor symptom
control or oversedation, if necessary. Over several days, dosing
intervals are transitioned from 6 hours to 12 hours. From
2006 to 2014, only 4% of MAiN infants were oversedated,
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and 2% needed adjuvant medication.16 Discharge criteria
include no signs of oversedation for 48 hours, abstinence
scores consistently below 8 on the Finnegan scale, weight
increasing or stable, adequate feeding pattern/milk intake,
stable vital signs for at least 24 hours, normal voiding and
stooling patterns, social issues related to home disposition
are resolved, and an appointment has been established with
a medical home. When an infant meets criteria for dis-
charge, a weaning calendar is developed by a pediatric
pharmacist. Methadone is dispensed in preﬁlled oral sy-
ringes at an average out-of-pocket cost to the family of $13
per one-month supply. Caregivers are required to ﬁll the pre-
scription prior to discharge, and unit staff reconcile that all
necessary syringes have been dispensed and educate the care-
givers on how to administer medication.
During the outpatient weaning period, the dosage is
reduced approximately 15% every Sunday and Wednes-
day. Weekly office visits occur at an outpatient pediatric
medical home during weaning to evaluate the effect of slow
methadone reduction. Outpatient physicians assess signs or
symptoms of poor NAS control and have the option to slow
the weaning process. A regional health department office pro-
vides one or two home visits, and families are educated about
signs of uncontrolled withdrawal that should prompt addi-
tional visits. All newborns are referred for developmental
assessment at 3–4 months of age, as well as to phone-based
parenting support and developmental screening services avail-
able until the child reaches 8 years of age.
Study Population and Data Sources
This was a retrospective cohort study to compare the NAS
infants who were treated with the MAiN model to other
similar NAS infants in South Carolina who were treated with
traditional care. MAiN infants were identiﬁed retrospec-
tively frommedical records from the study hospital. The study
hospital contains 710 beds and is part of a larger, public not-
for-proﬁt academic medical center. From 2006 through 2014,
the study hospital experienced average annual births of 5,221
infants.
The comparison group was retrospectively selected from
South Carolina statewide databases from the same time frame
(2006–2014). De-identiﬁed sociodemographic and clini-
cal data on MAiN infants, as well as South Carolina NAS
infants not treated with MAiN, were obtained from state-
wide databases. South Carolina all-payer inpatient
hospitalization and emergency department (ED) encoun-
ter data were linked with birth certiﬁcate andMedicaid claims
data by a state-issued identiﬁer. The linked data sets in-
cluded any inpatient, outpatient, or ED encounters within
six months of birth for infants born from 2006 to 2014 and
any inpatient, outpatient, or ED visit encounter by the in-
fant’s mother from the initial prenatal care visit through
delivery. The linked database also contained prescription
claims for Medicaid recipients. Institutional Review Board
approval was obtained prior to the study.
Within the linked statewide database, NAS infants were
ﬁrst identiﬁed using International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM)
codes 779.5 and/or 760.72 in one of 14 discharge diagno-
sis ﬁelds. The ICD-9-CM code 779.5 is deﬁned as “drug
withdrawal syndrome in newborn,” and the ICD-9-CM code
760.72 as “narcotics affecting fetus or newborn via placen-
ta or breast milk.” The hospitalization related to birth was
distinguished using ICD-9-CM codes (V30.00 to V39.01
with the last two digits of “00” or “01”) and its inpatient
status.
As shown in Figure 1, the comparison group was se-
lected from the statewide databases by ICD-9-CM codes and
then by the MAiN eligibility criteria. To determine which
of the identiﬁed state NAS infants would be potentially el-
igible for the MAiN model, we considered, according to
MAiN model eligibility criteria, infants with at least 35 weeks
gestational age and born to a mother diagnosed with opioid
dependence (ICD-9-CM codes 304.00, 304.01, 304.02,
304.03) during the pregnancy. Infants characterized by one
of the following abnormal conditions were excluded because
treatment in a Mother/Baby Unit setting would have been
unlikely due to these complications: (1) assisted ventila-
tion (6 hours), (2) surfactant replacement therapy, (3) and/
or seizure. Infants born at the study hospital were also
excluded from the state NAS sample. Infants treated in neo-
natal intensive care units (NICUs) were not excluded because
treatment protocols vary, and infants treated on the Mother/
Baby Unit by MAiN are likely to have been treated in NICUs
elsewhere. As previously reported, in the MAiN group 82%
of mothers received methadone, and 18% received
buprenorphine.16 Medication information was not avail-
able for the comparison group.
Demographic and Clinical Information
Demographic and clinical characteristics of the mothers and
infants, such as child’s sex, child’s gestational age, plurality
of birth, mother’s race, mother’s education level, and moth-
er’s age, were obtained from state birth certiﬁcate ﬁles.
Infections during pregnancy included gonorrhea, syphilis,
herpes, and chlamydia. Prenatal care usage was measured by
the Kotelchuck Adequacy of Prenatal Care Utilization Index,
which is a measure of prenatal care that takes into account
the timing of prenatal care initiation and services received
and combines these dimensions into one single score.20
Outcome Measures
The study outcome measures addressed medical and safety
outcomes, health services utilization, child protective ser-
vices involvement, and emergency services utilization. Medical
and safety outcomes were identiﬁed by the following ICD-
9-CM codes: abnormal loss of weight (783.21); adverse effect
of other drug, medicinal and biological substance (995.29);
cerebral irritability (779.1); convulsions (779.0, 780.3); diaper
or napkin rash (691.0); failure to thrive (783.41); feeding
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difficulty (779.3x); suffocation (E913.9); and unspeciﬁed fall
(E888.9). Health services utilization included length of hos-
pital stay (patient encounter data), total charges (patient
encounter data), the level of treatment nursery (patient en-
counter data), and breastfeeding (state birth certiﬁcate data).
Information about child protective services involvement was
provided by the South Carolina Department of Social Ser-
vices as the number of intakes per child if a case had been
opened.
Emergency services utilization and inpatient readmis-
sions that occurred from day 1 to 60 days after discharge
were obtained. Only the month and year of each visit was
provided, so for each infant, ED visits and readmissions oc-
curring in the month of discharge from the initial birth
hospitalization or the following month were captured and
reported. ED visits and inpatient readmissions were classi-
ﬁed as likely NAS related, possibly NAS related, or not NAS
related based on physician review of the diagnoses associated
with each encounter. Visits classiﬁed as likely NAS related
were identiﬁed by at least one of the following ICD-9-CM
codes related to effects of narcotics or drug withdrawal/
dependence: 292.0, 304.90, 760.72, and 779.5. Visits
classiﬁed as possibly NAS related were for diagnoses such
as diarrhea, feeding problems, vomiting, esophageal reﬂux,
and weight loss in addition to central nervous system symp-
toms such as involuntary movements, convulsions, epilepsy,
myoclonus, fussy baby, and excessive crying.
Statistical Analyses
Results of descriptive analyses were expressed as mean (stan-
dard deviation), median (interquartile range [IQR]), or
percentage. The differences between the MAiN infants and
the state comparison group were examined using either the
t-test for continuous normally distributed variables, the two-
sample Wilcoxon rank-sum test for skewed variables, or the
χ2 test for categorical variables (α = 0.05). Multivariate analysis
State Comparison Group Selection Criteria Based on Managing
Abstinence in Newborns (MAiN) Eligibility
Figure 1: State records were available for 110 infants treated with the MAiN model. Among 2,496 neonatal abstinence
syndrome (NAS) infants identified in South Carolina during the study period, 356 were used as the comparison group (tra-
ditional care NAS). ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.
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was not conducted because of the small sample size and highly
skewed data. Analysis of outcomes was performed using Stata
14.2 (StataCorp LP, College Station, Texas).
RESULTS
MAiN Model and Comparison Groups
State records were available for 110 infants treated with the
MAiN model. Among 2,496 NAS infants identiﬁed in South
Carolina during the study period, 356 were used as the com-
parison group (traditional care NAS infants) (Figure 1). The
number of state NAS infants identiﬁed as MAiN eligible in-
creased dramatically during the study period (Figure 2).
The comparison group for the study was drawn from
South Carolina inpatient health facilities with capacity to
handle deliveries. As expected, a signiﬁcant portion (44.9%)
(160/356) of state infants classiﬁed as potentially MAiN el-
igible were born at facilities with level III nurseries. Forty-
nine percent were delivered at hospitals with level II nurseries.
Although size of hospitals in the comparison group varied,
birth-related services provided can be expected to be rela-
tively consistent across the institutions.
Demographic and Clinical Characteristics
The demographic and clinical characteristics of NAS infants
and their mothers are summarized in Table 1. There was no
difference in the MAiN infants and the traditional care NAS
infants on the basis of infant’s sex (χ2 [df = 1] = 0.51;
p = 0.48), race (χ2 [df = 2] = 0.51; p = 0.29), birthweight
(t [df = 464] = 0.13; p = 0.90), or Medicaid status
(χ2 [df = 1] = 0.01; p = 0.91). Infants in the MAiN group
had a signiﬁcantly higher mean gestational age 38.6 (1.6)
than infants in the traditional care group 38.2 (1.6)
(t [df = 463] = 2.54; p = 0.01).
Demographic and clinical characteristics of the mothers
were similar between the MAiN infants and traditional
care NAS infants for the following aspects: age
(t [df = 464] = −0.51; p = 0.61), education attained (χ2
[df = 3] = 6.76; p = 0.08), Kotelchuck Adequacy of Prena-
tal Care Utilization index (χ2 [df = 3] = 7.82; p = 0.05), and
Women, Infants, and Children (WIC) recipient status (χ2
[df = 2] = 4.65; p = 0.10). However, the mothers of MAiN
infants had higher rates of infections during pregnancy (χ2
[df = 1] = 11.11; p < 0.001), tobacco use during pregnan-
cy (χ2 [df = 1] = 7.28; p = 0.007), and tobacco use prior to
pregnancy (χ2 [df = 1] = 10.76; p = 0.001) than mothers of
traditional care NAS infants.
Newborn Outcomes
Newborn outcomes are presented in Table 2. There was no
signiﬁcant difference in the proportion infants who were
breastfed in the MAiN (43.6%; 48/110) and traditional care
(48.9%; 174/356) groups (χ2 [df = 2] = 1.14; p = 0.57). There
was a signiﬁcantly higher proportion of infants who had at
least one case of child protective services involvement in the
MAiN group (32.7%; 36/110) compared to the tradition-
al care group (23.3%; 83/356) (χ2 [df = 1] = 3.92; p = 0.048).
While all MAiN infants were treated in level I care, 68.8%
(245/356) of traditional care NAS infants received treat-
ment in a level II–IV nursery.
The MAiN infants accumulated signiﬁcantly less in total
charges, with a median of $10,058 (IQR: $7,935–$11,518),
compared to a median of $18,262 (IQR: $5,816–$40,922)
in the traditional care group (z = −4.75; p < 0.001). The
median LOS for the MAiN group was 8 days (IQR: 6–10),
compared to a median LOS of 9 days (IQR: 4–18) for the
traditional care group (z = −1.49; p = 0.14).
State Neonatal Abstinence Syndrome Cases Classified as Managing
Abstinence in Newborns (MAiN) Eligible by Year
Figure 2: The number of state neonatal abstinence syndrome infants identified as MAiN eligible increased dramatically
during the study period.
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MAiN infants and the traditional care NAS infants also
had similar medical outcomes: cerebral irritability (0 vs. 0),
convulsions (1 vs. 0), feeding difficulty (11/110 [10.0%] vs.
43/356 [12.1%]; χ2 [df = 1] = 0.35; p = 0.55), and failure
to thrive (0 vs. 0). Compared to traditional care infants,
MAiN infants were coded more often for abnormal loss of
weight (4/110 [3.6%] vs. 3/356 [0.8%]; χ2 [df = 1] = 4.43;
p = 0.04) and diaper rash (20/110 [18.2%] vs. 33/356 [9.3%];
χ2 [df = 1] = 6.62; p = 0.01).
Regarding safety outcomes, none of the following events
were identiﬁed for either group: suffocation; unspeciﬁed
adverse effect of other drug, medicinal and biological sub-
stance; or unspeciﬁed fall.
Emergency Services Utilization and Inpatient
Readmissions
The emergency services utilization and inpatient readmis-
sions results are presented in Figure 3. In the MAiN group,
there were 31 ED visits and 13 inpatient readmissions. In
the state traditional care NAS group, there were 67 ED visits
and 44 inpatient readmissions. Of the MAiN infants, 2.7%
(3/110) had an ED visit that was assessed as likely or possibly
Table 1. Comparison of Neonatal Abstinence Syndrome Newborns and Mothers’ Demographic and Clinical Char-
acteristics, Managing Abstinence in Newborns (MAiN) vs. State Comparison Group
MAiN (N = 110) State (N = 356) P Value
Infants
Female, % (n) 49.1 (54) 45.2 (161) 0.48
Race and ethnicity, % (n)
White 93.6 (103) 93.5 (333) 0.29
Black or African American 2.7 (3) 5.6 (20)
Hispanic or Latino 0.9 (1) 0.6 (2)
Other 2.7 (3) 0.3 (1)
Gestational age, mean (SD) 38.6 (1.6) 38.2 (1.6) 0.01
Birth weight (grams), mean (SD) 2,953.7 (464.7) 2,946.6 (503.4) 0.90
Low birth weight (<2,500 g), % (n) 18.2 (20) 20.5 (73) 0.59
Insured by Medicaid, % (n) 91.8 (101) 92.1 (328) 0.91
Mothers
Age, mean (SD) 27.6 (5.1) 27.9 (5.0) 0.61
Education attained, % (n)
Less than high school graduate 26 (29) 25.8 (92) 0.08
High school graduate or GED 35 (38) 34.6 (123)
Some college credit 36 (40) 29.5 (105)
Associate’s or bachelor’s degree 3 (3) 9.8 (35)
Infections during pregnancy, % (n) 16.4 (18) 6.2 (22) <0.001
Kotelchuck Prenatal Care Index, % (n)
Inadequate 50.0 (55) 45.2 (161) 0.05
Intermediate 11.8 (13) 5.9 (21)
Adequate/Adequate Plus 38.2 (42) 47.2 (168)
Unknown 0 (0) 1.7 (6)
Tobacco use during pregnancy, % (n) 74.5 (82) 60.4 (215) 0.007
Tobacco use prior to pregnancy, % (n) 77.2 (85) 60.4 (215) 0.001
WIC recipient, % (n) 64.5 (71) 66.9 (238) 0.10
SD, standard deviation; WIC, Women, Infants, and Children (Special Supplemental Nutrition Program).
Table 2. Comparisons of Newborn Outcomes, Managing Abstinence in Newborns (MAiN) vs. State Comparison
Group
MAiN (N = 110) State (N = 356) P Value
Health Services Outcomes
Breastfed, % (n) 43.6 (48) 48.9 (174) 0.57
Length of stay in days, median (IQR) 8 (6–10) 9 (4–18) 0.14
Total charges in dollars, median (IQR) 10,058 (7,935–11,518) 18,262 (5,816–40,922) <0.001
Child Protective Services Involvement
At least one case opened, % (n) 32.7 (36) 23.3 (83) 0.048
IQR, interquartile range.
ARTICLE IN PRESS
6 Julie Summey, EdD, et al Early Treatment Innovation of Opioid-Dependent Newborns
NAS related, compared to 7.6% (27/356) of infants in the
traditional care group. Approximately 6% of infants in both
the MAiN and traditional care groups had a likely or pos-
sibly NAS related inpatient readmission.
For the MAiN group, the risk of an ED visit for a likely/
possibly NAS–related diagnosis was 4.6%, compared to 7.9%
for the traditional care group. For the MAiN group, the risk
of readmission for a likely/possibly NAS–related diagnosis
was 7.3%, compared to 9.8% for the traditional care group.
In addition, in the traditional group, two cases of sudden
infant death syndrome (SIDS) and one case of unattended
death were documented by ICD-9-CM codes in the ED visits
and readmissions, compared to no cases of SIDS or unat-
tended death in the MAiN group.
The median total charges per ED visit were $833 (IQR:
$528–$1,826) for the MAiN group and $581 (IQR: $280–
$1,377) for the traditional care group (z = −1.58; p = 0.11).
The median total charges per inpatient readmission were
$6,154 (IQR: $3,694–$8,321) for the MAiN group, which
was signiﬁcantly lower than the $16,891 (IQR: $9,551–
$47,503) median total charges for the traditional care group
(z = 3.58; p < 0.001). The median LOS for an inpatient re-
admission for the MAiN group was 7 days (IQR: 6–8),
compared to a median of 4 days (IQR: 2–12.5) for the tra-
ditional care group (z = −1.44; p = 0.15).
DISCUSSION
This is the ﬁrst known study to compare infants receiving
early initiated methadone (within 48 hours of birth) with
a historical comparison group. This analysis showed that
MAiN infants were similar with respect to outcomes, quality,
and safety when compared to potentially MAiN–eligible
infants receiving traditional care in South Carolina.
There was no difference in medical and safety outcomes
between MAiN and traditional care NAS infants, with the
exception of slightly more abnormal weight loss and diaper
rash in the MAiN group. For these relatively minor health
outcomes, differences may reﬂect documentation and coding
variability rather than true differences in incidence. Overall,
these ﬁndings are consistent with previous retrospective studies
that showed outpatient methadone weaning strategies are not
associated with increased risk of adverse outcomes.12,21 We
also found that neither MAiN infants nor traditional care
NAS infants had documented ICD-9-CM codes for adverse
safety events. The results that we report for MAiN infants
are consistent with evidence that oral methadone therapy for
inpatient neonates requiring pharmacologic treatment of NAS
supports symptom stabilization with rare occurrence of som-
nolence, respiratory depression, or oversedation.22,23 To date,
no studies regarding the safety of outpatient methadone dosing
have been conducted. Our ﬁndings add to a growing body
of evidence that comprehensive, provider-managed outpa-
tient weaning protocols can be safe and effective strategies
for caring for infants with NAS.12,21,24,25
In our study cohort, ED visits and hospital readmissions
up to two months from birth hospitalization discharge were
different among MAiN and traditional care NAS infants.
The traditional care group had a higher percentage of ED
visits and inpatient readmissions assessed as likely or possi-
bly NAS related than the MAiN group. While the current
study examined ED visits and readmissions up to two months
of discharge from hospital birth, Backes et al. report no dif-
ference in ED visits and hospital readmission rates within
12 months between patients receiving standard inpatient treat-
ment and those in a combined inpatient/outpatient weaning
group.12 The MAiN model differs from other models used
Comparisons of Emergency Services Utilization and Readmissions Between Managing Abstinence in Newborns
(MAiN) and State Comparison Group Within up to 60 Days of Birth Hospitalization Discharge
Figure 3: The emergency services utilization and inpatient readmissions results are presented. In the MAiN group, there
were 31 emergency department (ED) visits and 13 inpatient readmissions. In the state traditional care neonatal abstinence
syndrome (NAS) group, there were 67 ED visits and 44 inpatient readmissions.
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in hospitals in the United States, which makes comparing
ED visit and readmission rates difficult.
The most striking differences between the two groups were
related to health services utilization outcomes. Most notably,
there was a signiﬁcant difference in hospital charges. The state
group had median charges $8,204 higher than the MAiN
population for the birth hospitalization and $10,737 higher
median charges for any hospital readmissions (p < 0.001).
Research on combined inpatient/outpatient methadone
weaning protocols has documented similar charge and LOS
reductions. Lee et al. found that infants completing com-
bined outpatient weaning treatment had an average LOS of
11.4 days vs. 25.1 days for infants completing treatment in
the hospital, resulting in a reduction of approximately $29,150
in charges per infant.21 Lai et al. report an average LOS of
11.8 days for patients who underwent combined inpatient/
outpatient wean and mean hospital charges of $58,400 per
patient.26 National data from 2012 showed that pharmaco-
logically treated NAS infants had mean hospital charges
totaling $93,400.9
Although the number of newborns in this study was small,
NAS cases in the state and nation continue to rise at an alarm-
ing rate.9,10 There is a clear, upward trend in length of hospital
stay and resource utilization for infants requiring NAS
treatment.27 If statewide NAS births continue to increase,
predicted hospital charges are expected to total more than
$57,000 per infant.28 Assuming current growth trends of state
and national NAS cases, South Carolina and the rest of the
United States should also expect exponential resource uti-
lization growth.
There is a national impetus for nurseries to implement
policies and standardized approaches to caring for substance-
exposed newborns and mothers with substance use disorders.14
Goals for improved protocols would include decreased trans-
fers to tertiary care facilities, improved and sustained treatment
in the community, and decreased readmission risk.29 Recent
research shows that standardizing treatment approaches has
positive beneﬁts for NAS neonates and decreases health care
utilization.30–32 MAiN provides a comprehensive approach
to caring for opioid-dependent newborns and their mothers
that may be replicated and customized in low-acuity nurs-
eries around the country. Transitions from per diem to
diagnosis-related group and bundled care reimbursement
systems should further stimulate trends toward standard-
ized care for NAS infants and their mothers. Meanwhile,
additional problems exist, including high utilization of NICU
beds, with up to 50% of NICU beds being used for NAS
patients.29
Limitations
There are several limitations in this study that should be noted.
The MAiN infants are a group with the highest likelihood
of having withdrawal symptoms. Mothers of infants in the
traditional care group were diagnosed with opioid depen-
dence, but it is not known whether mothers were dependent
on short- or long-acting opioids, or whether mothers were
also using nicotine or SSRIs (selective serotonin reuptake in-
hibitors), which have been shown to increase NAS risk.Thus,
this comparison group is diluted with lower risk compared
to the MAiN infants, all of whom were exposed to at least
20 mg ofmethadone per day or at least 9 mg of buprenorphine
per day for at least two weeks immediately prior to delivery.
Individual South Carolina physicians can choose to treat
NAS infants, and infants identiﬁed by ICD-9-CM code may
or may not have received treatment for NAS. Because this
was a retrospective cohort study using data from state records,
data limitations exist. For example, the state comparison group
of NAS infants identiﬁed as MAiN eligible was based on avail-
able data from state records, which depended on the reliability
of mothers being coded as opioid dependent and subject to
errors of omission related to safety or medical outcomes. Avail-
able data were limited to ICD-9-CM diagnosis codes. In
addition, the availability of data on ED visits and readmis-
sions was such that the research team was not able to
determine the number of days between birth discharge and
the speciﬁc return ED visit or readmission. Only the month
and year of these visits was available.
NAS infants treated with the MAiN model were similar
in demographic and clinical characteristics to similar NAS
infants treated with traditional care in South Carolina during
the study period. Mothers of infants in both the MAiN and
traditional care were similar, with the exception of tobacco
use and infections during pregnancy, both of which were more
common in MAiN mothers. However, it should be noted
that this study has a non-randomized design, so there exists
the possibility of unmeasured confounders. Thus, this should
be considered as a hypothesis-generating study.
Planned future research include a prospective study with
standardized data collection instruments, allowing the re-
search team to capture real-time data instead of relying on
administrative/billing data. Ideally, a randomized con-
trolled trial would be performed to determine the efficacy
of the MAiN model. In addition, study of long-term out-
comes associated with the opioid withdrawal experience and
of infants treated with methadone is warranted.
CONCLUSION
Alarming increases in NAS provide impetus for standard-
ized approaches to caring for substance-exposed newborns
and mothers with substance use disorders. With no differ-
ence in medical and safety outcomes and a signiﬁcant
reduction in charges, the MAiN model can be considered
safe and cost-effective. This study demonstrates the poten-
tial value of implementing the MAiN model more widely
across South Carolina and the rest of the United States, but
further randomized controlled studies are warranted. Ben-
eﬁts of widespread implementation may include signiﬁcant
cost reduction over the long term and standardization of care
without sacriﬁcing safety.
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